HIV-associated lipodystrophy, or lipodystrophy is a syndrome that occurs in HIV patients. It is characterized by the loss of fat from the arms, legs, buttocks, and face. However, the exact cause of HIV-associated lipodystrophy is not known, some evidence suggests that it occurs in HIV-infected patients who are subjected to antiretroviral drugs. As per 2014 National Center for Biotechnology Information (NCBI) report, the prevalence of lipodystrophy in HIV-infected patients varies between 10% and 80%. Thus, there is an increasing demand for HIV-associated lipodystrophy treatment worldwide.
Get a Sample Copy of the Report 2021 @
The report provides key statistics on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.The data contains the company profile, Y-O-Y turnover, product type and services, income generation, which offers direction to businesses to take crucial steps.
Major Players in HIV-Associated Lipodystrophy Treatment Market
Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.
Rise in cases of HIV worldwide is expected to propel the growth of the global HIV-associated lipodystrophy treatment market during the forecast period. According to the report published by Journal of AIDS & Clinical Research, in 2014, there are around 32.4-88.6% of people that have HIV-associated lipodystrophy. Moreover, as reported by the World Health Organization (WHO), in 2017, worldwide, more than 35 million people were suffering from HIV and around one million died in 2016 because of HIV.
Furthermore, introduction of novel drugs to treat HIV-associated lipodystrophy is expected to augment the growth of the global HIV-associated lipodystrophy market. For instance, in 2014, Theratechnologies Inc. announced that the company has received a regulatory approval (notice of compliance) from Health Canada for EGRIFTA (tesamorelin for injection). EGRIFTA had also received the U.S. Food and Drug Administration (FDA) approval in 2010.
Ask for PDF sample copy of the report @
Lack of awareness among people about available drugs and limited access to drugs is expected to hamper the growth of the global HIV-associated lipodystrophy market. As reported by the United Nations Program on HIV and AIDS (UNAIDS) in 2016, it was found that more than 36.7 million people worldwide had HIV; out of which 30% of the population was unaware of this condition. Moreover, the prevalence of HIV in some parts of the world, such as Africa, is high, but the availability of drugs is limited, which in turn is expected to hinder growth of the market in this region.
Among regions, North America is expected to witness strong growth in the global HIV-related lipodystrophy treatment market due to the introduction of insurance policies that cover HIV-related lipodystrophy. For instance, in 2016, the Massachusetts House and Senate signed a law mandating insurance coverage for a debilitating side effect of old HIV drugs.
Europe is also expected to witness robust growth in the global HIV-related lipodystrophy treatment market due to increasing prevalence of HIV in this region. For instance, according to NCBI, in 2014, around 860,000 adults in Europe were living with HIV and he highest prevalence of HIV were found in France, Spain, Greece, and Germany.
Reasons to Purchase this Report
• To gain an in-depth understanding of HIV-Associated Lipodystrophy Treatment market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, HIV-Associated Lipodystrophy Treatment market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Buy This Complete A Business Report With Flat US $2000 Off @
Table of Content
Global HIV-Associated Lipodystrophy Treatment Market Research Report
Section 1: Global HIV-Associated Lipodystrophy Treatment Industry Overview
Section 2: Global Economic Impact on HIV-Associated Lipodystrophy Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: HIV-Associated Lipodystrophy Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global HIV-Associated Lipodystrophy Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027